Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2025)
Historic Accumulated Expenses for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $18.4 million.
- Denali Therapeutics' Accumulated Expenses rose 2342.34% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 2342.34%. This contributed to the annual value of $24.7 million for FY2024, which is 6390.02% down from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Accumulated Expenses is $18.4 million, which was up 2342.34% from $12.1 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Accumulated Expenses registered a high of $68.5 million during Q4 2023, and its lowest value of $5.8 million during Q1 2022.
- Moreover, its 5-year median value for Accumulated Expenses was $10.5 million (2021), whereas its average is $17.7 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 25076.53% in 2022, then crashed by 6390.02% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Accumulated Expenses stood at $19.0 million in 2021, then surged by 250.77% to $66.7 million in 2022, then rose by 2.71% to $68.5 million in 2023, then plummeted by 63.9% to $24.7 million in 2024, then decreased by 25.76% to $18.4 million in 2025.
- Its last three reported values are $18.4 million in Q3 2025, $12.1 million for Q2 2025, and $7.7 million during Q1 2025.